+++
title = "United Health Products Elevates to OTCQB Venture Market Amid FDA Regulatory Challenges"
date = "2025-05-01T12:45:20Z"
draft = false
summary = "United Health Products, Inc. transitions to the OTCQB Venture Market to enhance investor visibility while navigating FDA regulatory hurdles for its CelluSTAT Hemostatic Gauze."
description = "United Health Products, Inc. successfully uplists shares to OTCQB Venture Market, signaling progress towards FDA approval for CelluSTAT Hemostatic Gauze. CEO Brian Thom highlights benefits of increased visibility and liquidity."
source_link = "https://www.newmediawire.com/news/united-health-products-announces-otcqb-uplisting-and-fda-update-7080580"
enclosure = "https://cdn.newsramp.app/banners/health-wellness-3.jpg"
article_id = 93094
feed_item_id = 13686
url = "/202505/93094-united-health-products-elevates-to-otcqb-venture-market-amid-fda-regulatory-challenges"
qrcode = "https://cdn.newsramp.app/newmediawire/qrcode/255/1/rift68qq.webp"
source = "NewMediaWire"
+++

<p>United Health Products, Inc. (OTCQB: UEEC) has achieved a notable advancement by moving its stock to the OTCQB Venture Market, marking a pivotal step in its strategy to increase investor engagement and improve trading liquidity. This transition, effective May 1, 2025, signifies the company's progression from the OTC 'Pink' market, retaining its ticker symbol 'UEEC'. The OTCQB Venture Market, overseen by OTC Markets Group Inc., serves as a platform for emerging companies and is acknowledged by the SEC as an established public market, offering a layer of credibility and transparency to its listed entities.</p><p>CEO Brian Thom highlighted the significance of this move, underscoring the company's dedication to transparency and its appeal to a broader investor base. The OTCQB listing mandates adherence to stringent SEC financial reporting and an annual verification process, requirements that United Health Products is prepared to meet, signaling its commitment to corporate governance and investor confidence.</p><p>Concurrently, the company faces a regulatory challenge with the FDA concerning its Investigational Device Exemption (IDE) application for the CelluSTAT Hemostatic Gauze. The FDA's decision to not approve the IDE application, based on findings from Bioresearch Monitoring audits of a 2019 clinical study, presents a hurdle. However, United Health Products is actively engaging with the FDA, scheduling a teleconference to address and resolve the cited issues, demonstrating its proactive stance in navigating regulatory pathways.</p><p>Despite these challenges, the company continues to advance preparatory tasks for its clinical study, focusing on areas not requiring immediate IDE approval. The CelluSTAT Hemostatic Gauze, an all-natural solution aimed at controlling mild to moderate bleeding, remains central to the company's mission. The outcome of the ongoing FDA review process is crucial, as it will determine the product's eligibility for the human surgical market, potentially opening new avenues for growth and innovation in medical technology.</p><p>This development is significant for business and technology leaders, as it underscores the intersection of corporate strategy, regulatory navigation, and technological innovation in the healthcare sector. The move to the OTCQB Venture Market enhances United Health Products' visibility among investors, while the resolution of FDA regulatory challenges could pave the way for breakthroughs in medical technology, impacting the industry and patient care.</p>